Specified Drug Use-results Survey of Betanis Tablets for Patients With Coexisting Cardiovascular Disease

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)

NCT02216214 ·Status: COMPLETED ·Phase: PHASE4

Therapeutic Efficacy and Safety of Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan

NCT03044912 ·Status: UNKNOWN ·Phase: PHASE3

Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

NCT00689104 ·Status: COMPLETED ·Phase: PHASE3

Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan

NCT03059134 ·Status: COMPLETED ·Phase: PHASE3

Comparisons of the Effects of Solifenacin Versus Mirabegron on Autonomic System, Arterial Stiffness and Psychosomatic Distress and Clinical Outcomes

NCT02540707 ·Status: COMPLETED ·Phase: PHASE4

Cardiovascular Morbidity During Treatment of Overactive Bladder With B3 Agonists

NCT02622555 ·Status: COMPLETED

A Study to Evaluate the Effect of Mirabegron + Solifenacin in Overactive Bladder Patients

NCT01745094 ·Status: COMPLETED ·Phase: PHASE4

A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB)

NCT02386072 ·Status: COMPLETED

A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)

NCT02138747 ·Status: COMPLETED ·Phase: PHASE4

Beta-3 Agonist and Anti-muscarinic Agent for Sjogren's Syndrome With Overactive Bladder

NCT04909255 ·Status: UNKNOWN ·Phase: PHASE4

Study to Test the Long Term Safety and Efficacy of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

NCT00688688 ·Status: COMPLETED ·Phase: PHASE3

A Study to Evaluate the Efficacy and Safety of Mirabegron Compared to Solifenacin in Patients With Overactive Bladder Who Were Previously Treated With Another Medicine But Were Not Satisfied With That Treatment.

NCT01638000 ·Status: COMPLETED ·Phase: PHASE3

A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder

NCT04562090 ·Status: COMPLETED ·Phase: PHASE4

Efficacy and Safety of the Mirabegron Compared With Solifenacin in Treatment of Overactive Bladder

NCT03558919 ·Status: COMPLETED ·Phase: PHASE4

A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder

NCT00912964 ·Status: COMPLETED ·Phase: PHASE3

Impact of Beta-3 Agonist on Psychological Distress and Blood Flow of the Bladder in Women With Overactive Bladder Syndrome

NCT03695822 ·Status: WITHDRAWN ·Phase: PHASE4

A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice

NCT02320773 ·Status: COMPLETED

MIrabegron With oveRACtive bLadder Symptoms in mEn

NCT02361502 ·Status: UNKNOWN ·Phase: PHASE4

Study of ONO-8577 in Patients With Overactive Bladder

NCT03106623 ·Status: COMPLETED ·Phase: PHASE2

Myrbetriq™ (Mirabegron) to Improve Disordered Sleep in Subjects With Lower Urinary Tract Symptoms (LUTS)

NCT02410135 ·Status: COMPLETED

Mirabegron Combined With Behavioral Intervention for Overactive Bladder：a Prospective Multicenter Randomized Controlled Clinical Study

NCT05452434 ·Status: UNKNOWN ·Phase: PHASE4

Pharmacologic Effect for Female Overactive Bladder Syndrome: Mirabegron Versus Solifenacin

NCT04023253 ·Status: UNKNOWN ·Phase: PHASE3

Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women

NCT02981459 ·Status: WITHDRAWN ·Phase: PHASE4

A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder

NCT01340027 ·Status: COMPLETED ·Phase: PHASE2

Mirabegron for Female OAB Patients: Comparison of Daytime and Nighttime Dosing

NCT03251300 ·Status: UNKNOWN ·Phase: PHASE4